- Home
- STRO vs PRQR Comparison
STRO vs PRQR Comparison
Compare STRO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | PRQR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 250.7M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | STRO | PRQR |
|---|---|---|
| Price | $9.92 | $2.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $18.29 | $8.14 |
| AVG Volume (30 Days) | 121.9K | ★ 621.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,646,000.00 | $18,859,556.00 |
| Revenue This Year | $63.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $1.07 |
| 52 Week High | $21.50 | $3.10 |
Technical Indicators
Market Signals| Indicator | STRO | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 78.91 | 49.00 |
| Support Level | $9.53 | $2.15 |
| Resistance Level | $10.10 | $2.49 |
| Average True Range (ATR) | 0.93 | 0.18 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 98.52 | 52.17 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.